Basic Profile / Key Facts
Drug Category
Dosage Forms
- IM solution
- Powder for solution
Indications
For the treatment of acute leukaemia, malignant lymphoma, Hodgkin's disease, acute erythraemia and acute panmyelosis
Pharmacology
Vindesine is indicated for the treatment of acute lymphocytic leukemia of childhood that is resistant to vincristine and non-oat cell lung cancer.Vindesine causes the arrest of cells in metaphase mitosis. It is three times more potent than vincristine and nearly 10 times more potent than vinblastine in causing mitotic arrest in in vitro studies at doses designed to arrest from 10 to 15% of the cells in mitosis. Vindesine and vincristine are approximately equipotent at dose levels that arrest 40 to 50% of the cells in mitosis. Unlike vinblastine, vindesine produces very few postmetaphase cells. Vindesine has demonstrated activity in patients who have relapsed while receiving multiple-agent treatment that included vincristine.
Mechanism of Action
Vindesine acts by causing the arrest of cells in metaphase mitosis through its interaction with tubulin. The drug is cell-cycle specific for the S phase.
Absorption
Not Available
Toxicity
Not Available
Biotrnasformation / Drug Metabolism
Hepatic
Contraindications
Contraindications:
Vindesine is contraindicated in patients who are known hypersensitive to Vindesine, vinca alkaloids, or any component of the formulation.
Drug Interactions
Drug Interactions:
Vindesine can interact with the drugs of the following categories:
- Blood dyscrasia: can cause unpredictable myelotoxicity
- Bone marrow depressants: can cause a predictable dose-related myelotoxicity
- Radiation therapy: may cause marrow depression
- Neurotoxic medications: can cause neurologic toxicity
- Phenytoin: can increase seizure activity
- Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination,
and decrease patient's response to the vaccine
- Mitomycin-C: may cause shortness of breath and bronchospasm
- Killed virus vaccines: may decrease patient's response to the vaccine
|
